Leidos has been awarded a prime vaccine adjuvant development contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to improve the efficacy of vaccine candidates for prevention of anthrax and West Nile virus (WNV) disease. The contract has a one-year period of performance valued at $2.2 million, followed by four option years, for a total contract value of approximately $12.4 million, if all options are exercised.   Leidos h...